- Home
- SEAT vs OMER Comparison
SEAT vs OMER Comparison
Compare SEAT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- OMER
- Stock Information
- Founded
- SEAT 2001
- OMER 1994
- Country
- SEAT United States
- OMER United States
- Employees
- SEAT N/A
- OMER N/A
- Industry
- SEAT Industrial Machinery/Components
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- SEAT Industrials
- OMER Health Care
- Exchange
- SEAT Nasdaq
- OMER Nasdaq
- Market Cap
- SEAT 622.1M
- OMER 530.2M
- IPO Year
- SEAT N/A
- OMER 2009
- Fundamental
- Price
- SEAT $4.48
- OMER $9.13
- Analyst Decision
- SEAT Strong Buy
- OMER Buy
- Analyst Count
- SEAT 10
- OMER 4
- Target Price
- SEAT $6.73
- OMER $22.50
- AVG Volume (30 Days)
- SEAT 1.1M
- OMER 509.4K
- Earning Date
- SEAT 03-04-2025
- OMER 03-31-2025
- Dividend Yield
- SEAT N/A
- OMER N/A
- EPS Growth
- SEAT N/A
- OMER N/A
- EPS
- SEAT N/A
- OMER N/A
- Revenue
- SEAT $774,076,000.00
- OMER N/A
- Revenue This Year
- SEAT $10.17
- OMER N/A
- Revenue Next Year
- SEAT $4.02
- OMER N/A
- P/E Ratio
- SEAT N/A
- OMER N/A
- Revenue Growth
- SEAT 13.91
- OMER N/A
- 52 Week Low
- SEAT $3.24
- OMER $2.61
- 52 Week High
- SEAT $6.41
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- SEAT 49.56
- OMER 50.45
- Support Level
- SEAT $4.13
- OMER $8.28
- Resistance Level
- SEAT $4.78
- OMER $9.08
- Average True Range (ATR)
- SEAT 0.26
- OMER 0.58
- MACD
- SEAT -0.08
- OMER -0.05
- Stochastic Oscillator
- SEAT 26.67
- OMER 62.58
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.